How long do you stay on Mounjaro or Wegovy?
There is no universal finish date for Mounjaro or Wegovy. HSE guidance treats obesity medicines as potentially long-term treatment, with regular reviews of benefit, side effects and whether continuing still makes sense.
Health / The Compound journalPhoto: Towfiqu barbhuiya on Pexels · Illustrative image.
Ireland-focused adult weight-management guide · reviewed 29 September 2026. This is general information, not a recommendation to continue, reduce or stop a prescription. Decisions about duration belong with the prescriber who knows your health history.
If Mounjaro or Wegovy is working, a surprisingly difficult question eventually appears:
How long am I supposed to stay on it?
There is no universal answer such as six months, one year or “until you reach your goal weight”.
For obesity treatment, the more accurate way to think about these medicines is as potentially long-term treatment that is reviewed over time.
The HSE says medicines used to treat obesity are safe to take for a long time and that people taking them need regular check-ups so the doctor can assess whether the medicine is still working and whether side effects are occurring.
The World Health Organization likewise describes GLP-1 therapies as generally long-term treatments and conditionally recommends them for long-term treatment of adults with obesity as part of comprehensive care.
That does not mean everyone should stay on Mounjaro or Wegovy forever.
It means there is no automatic stopping date simply because a certain number of months has passed or a target weight has been reached.
The decision depends on whether treatment is still beneficial, tolerated, affordable and appropriate for the person taking it.
HSE: medicines to treat obesity
The short answer
For adult weight management:
- Mounjaro (tirzepatide) and Wegovy (semaglutide) are authorised for weight management that includes both weight loss and weight maintenance.
- The HSE describes obesity medicines as suitable for long-term use with regular medical review.
- WHO describes GLP-1 therapies as generally long-term treatments and says obesity requires comprehensive, lifelong care.
- Clinical trials show that substantial weight regain is common after treatment is withdrawn.
- There is still no high-quality evidence that defines one ideal treatment duration for every patient.
So the useful question is not simply:
“When do I stop?”
It is:
“At each review, is this medicine still doing enough good to justify continuing it?”
Why reaching your target weight does not automatically mean treatment is finished
Wegovy and Mounjaro are not authorised only to produce an initial drop in weight.
Their European indications explicitly include weight maintenance as part of weight management.
That distinction matters.
If a medicine is helping maintain a lower weight, reaching that lower weight does not necessarily mean the medicine has stopped doing anything. The treatment may be part of what is maintaining the result.
This is similar to the logic used with many chronic conditions: improvement while taking treatment does not by itself prove the treatment is no longer needed.
But obesity treatment is also individual. A person may need to stop or change treatment because of side effects, pregnancy planning, another health condition, cost, poor response or personal preference.
That is why regular review matters more than a fixed calendar date.
What happens when treatment stops?
The clearest evidence comes from withdrawal trials.
These studies do not tell us exactly what will happen to an individual person, but they show why stopping is not always the end of the weight-management problem.
Wegovy / semaglutide: STEP 1 extension
In the STEP 1 trial extension, adults with overweight or obesity had received semaglutide 2.4 mg for 68 weeks.
Among the extension participants, average weight loss during treatment was 17.3%.
One year after semaglutide and the structured lifestyle intervention were stopped, participants had regained about two-thirds of the weight they had previously lost on average.
Their mean body weight was still below the original baseline, but much of the treatment-period loss had returned. Several cardiometabolic improvements also moved back towards baseline.
That does not mean everyone regains two-thirds.
It is a group average from a particular study population and treatment setting.
But it is strong evidence that stopping semaglutide can be followed by substantial regain.
Mounjaro / tirzepatide: SURMOUNT-4
SURMOUNT-4 gives an even cleaner comparison because participants were randomised either to continue tirzepatide or switch to placebo after an initial treatment period.
After the first 36 weeks of tirzepatide, participants had lost an average 20.9% of body weight.
During the following 52 weeks:
- those who continued tirzepatide lost another 5.5% on average from the week-36 point;
- those switched to placebo regained 14.0% on average from that point.
At week 88, 89.5% of participants who continued tirzepatide maintained at least 80% of their initial weight loss, compared with 16.6% of those switched to placebo.
Again, those figures are not a personal forecast.
They show that, in this trial, continued treatment was much more effective at maintaining the initial weight reduction than withdrawal.
Does that mean you have to take it for life?
No trial can answer that question for every person.
The studies above lasted for defined periods. They do not prove that every patient needs the same medicine indefinitely.
WHO’s 2025 guideline is deliberately cautious.
It conditionally recommends GLP-1 therapies for long-term treatment of adults with obesity while highlighting evidence gaps around:
- very long-term efficacy;
- long-term safety;
- maintenance;
- discontinuation;
- affordability;
- and access.
WHO’s patient Q&A describes GLP-1 therapies as generally long-term treatments, meaning six months or longer, rather than short courses.
The key point is therefore not “lifelong injections are mandatory”.
It is that obesity is a chronic condition and stopping effective treatment can allow the biological drivers of weight regain to reassert themselves.
What should happen at regular reviews?
The HSE says people taking obesity medicines should have regular check-ups.
A useful review is broader than simply asking whether the number on the scales has fallen.
Depending on the person, the clinician may consider:
| Question | Why it matters |
|---|---|
| Is it still working? | Weight, waist measurements and obesity-related health conditions may all matter. |
| Are side effects manageable? | Benefit has to be weighed against tolerability and safety. |
| Has your health changed? | Other conditions, medicines or pregnancy plans can change what is appropriate. |
| Can treatment realistically continue? | Private cost and access are genuine parts of long-term treatment. |
| What happens if treatment changes? | Follow-up matters because regain is common after withdrawal. |
If side effects are part of the decision, see GLP-1 side effects: what is common and when to get help.
Is there a point where the medicine has “worked enough”?
Weight loss often slows or plateaus during treatment.
A plateau does not automatically mean the medicine has stopped working.
If someone has lost weight and is maintaining it, maintenance itself can be a treatment effect.
What matters clinically is whether the overall benefit remains worthwhile.
Conversely, continuing indefinitely simply because treatment was started also makes little sense if the medicine is not producing sufficient benefit, side effects are unacceptable or circumstances have changed.
There is no single percentage of weight loss on a website that can decide that for everyone.
What if you want to stop because of cost?
This is particularly relevant in Ireland because long-term private treatment can become expensive.
Our Wegovy, Mounjaro and Ozempic cost guide shows why a starter price can understate the longer-term bill as doses and pharmacy prices change.
The GLP-1 Cost Calculator can also model what a four-week price means over several months or a full year.
If cost is becoming unsustainable, tell the prescriber before you simply stop buying the medicine.
The HSE advises talking to your doctor if you are thinking of stopping. Options may include changing dose, changing medicine, stopping safely or exploring another obesity treatment.
Current Irish public-funding rules are explained separately in our HSE and Medical Card GLP-1 guide.
What if you stop after reaching your goal weight?
The withdrawal trials suggest this is exactly the point where a maintenance plan matters.
A lower body weight does not remove all of the physiological pressures that favour regain.
That does not mean regain is guaranteed or that everyone will return to their original weight.
It means that if medication is removed, some of the treatment effect is also being removed.
A sensible stopping conversation therefore includes what will replace the support that treatment was providing.
That might involve nutrition support, resistance training and physical activity, behavioural support, follow-up appointments or another clinically appropriate treatment.
The Nutrition Needs Calculator can help illustrate energy and protein needs, but it is not a substitute for an individual dietetic or medical plan.
What about muscle loss while staying on treatment?
Duration is not only about body weight.
When weight falls, some lean mass can also be lost.
For people using weight-management medicines long term, preserving function and muscle becomes increasingly important.
That makes adequate nutrition, sufficient protein and resistance exercise relevant parts of the broader treatment plan where clinically appropriate.
We will cover GLP-1s and muscle preservation in a separate evidence review rather than treating a generic protein target as suitable for everyone.
Pregnancy is a different situation
Pregnancy planning can require treatment to stop even if the medicine is otherwise working well.
Current European product information says semaglutide should be discontinued at least two months before a planned pregnancy, while tirzepatide should be discontinued at least one month before a planned pregnancy.
This deserves advance discussion with the prescriber, particularly if the medicine is also affecting diabetes management.
See our dedicated guide: GLP-1 medicines and pregnancy: Ozempic, Wegovy and Mounjaro.
What if you are taking Ozempic?
Ozempic also contains semaglutide, but its authorised role is different from Wegovy.
Ozempic is authorised for type 2 diabetes, while Wegovy is the semaglutide product authorised for weight management.
If someone is taking Ozempic for diabetes, duration cannot be decided only by what has happened to body weight. Blood glucose control and the wider diabetes treatment plan matter.
Our How to get Ozempic in Ireland guide explains that distinction.
Do not treat the trials as a stopping schedule
The evidence tells us something important:
continued treatment generally maintains weight loss better than withdrawal.
It does not tell you to:
- reduce a dose on a particular timetable;
- stretch injections further apart;
- restart at your previous dose after a long gap;
- use leftover medicine;
- or switch between Mounjaro and Wegovy without clinical advice.
Those are prescribing decisions.
Our separate guide on what happens when you stop a GLP-1 medicine goes deeper into the withdrawal evidence and what to discuss before the last prescription.
A practical way to think about duration
Instead of asking for a fixed finish date, think in review points.
At the start: Is this treatment appropriate and what outcome are we trying to achieve?
During dose adjustment: Is it tolerated and is the dose plan still appropriate?
After meaningful weight loss: Is treatment improving health as intended?
At a plateau: Is the medicine still helping maintain the result?
If circumstances change: Do cost, side effects, pregnancy plans, another illness or personal preference change the balance?
If stopping is considered: What is the follow-up plan, and what should happen if weight or other health markers begin moving in the wrong direction?
That approach fits the evidence better than treating Mounjaro or Wegovy as a fixed-length course.
The bottom line
There is no standard number of months after which everyone should stop Mounjaro or Wegovy.
For obesity, both medicines are used for weight management that includes maintenance, and Irish HSE guidance says obesity medicines can be taken long term with regular check-ups.
Withdrawal trials show why: substantial weight regain is common after semaglutide or tirzepatide is stopped.
But “long term” is not the same as “automatically forever”.
The right duration is the period during which the medicine remains appropriate, effective, tolerable and worth continuing, with the decision reviewed over time rather than set by a universal deadline.
